Compare Gigacloud Technology Inc (GCT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Novavax Inc — how do they compare? Gigacloud Technology Inc trades at $51.52 (market cap $1.84B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Gigacloud Technology Inc is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| GCT | NVAX | |
|---|---|---|
Market Cap | $1.84B | $1.30B |
Sector | Technology | Health |
52-Week High | $53.25 | $11.19 |
52-Week Low | $25.44 | $6.22 |
Enterprise Value | $1.97B | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $53.25, up 1.62% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.16 versus $0.90 expected, and maintains a 10.65% net income margin. Revenue growth is projected from $1.29B in 2025 to $1.5B in 2026, supported by positive cash flow generation of $120.10M in 2025.
The outlook remains positive given strong profitability metrics (32.34% ROE) and analyst consensus favoring Buy ratings (66.67%). Key risks include potential margin pressure from higher costs and competitive threats in the B2B logistics space. The stock's current valuation at 12.3x P/E appears reasonable relative to growth prospects, though technical indicators show overbought conditions with RSI above 85.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
